Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  American Journal of Psychiatry

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1176/appi.ajp.163.11.1905PMID 17074942
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Medication augmentation after the failure of SSRIs for depression.

  2006cited by this paper
• Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

  2006cited by this paper
• Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

  2006cited by this paper
• A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report.

  2006cited by this paper
• Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.

  2006cited by this paper
• An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report.

  2006cited by this paper
• A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report.

  2006cited by this paper
• Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review.

  2006cited by this paper
• Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features.

  2005cited by this paper
• Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D.

  2005cited by this paper
• Self-Reported Depressive Symptom Measures: Sensitivity to Detecting Change in a Randomized, Controlled Trial of Chronically Depressed, Nonpsychotic Outpatients

  2005cited by this paper
• Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.

  2004cited by this paper
• The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder.

  2004cited by this paper
• The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation

  2004cited by this paper
• Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D

  2004cited by this paper
• Diagnosis and definition of treatment-resistant depression.

  2003cited by this paper
• Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.

  2003cited by this paper
• The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.

  2003cited by this paper
• Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design.

  2003cited by this paper
• Do the epilepsies, pain syndromes, and affective disorders share common kindling-like mechanisms?

  2002cited by this paper
• The Expert Consensus Guideline Series. Treatment of depression in women.

  2001cited by this paper
• Clinical guidelines for the treatment of depressive disorders. II. Principles of management.

  2001cited by this paper
• Strengthening clinical effectiveness trials: equipoise-stratified randomization.

  2001cited by this paper
• Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology.

  2000cited by this paper
• Treatment resistant depression: methodological overview and operational criteria.

  1999cited by this paper
• Strategies and tactics in the management of maintenance treatment for depressed patients.

  1999cited by this paper
• The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder.

  1999cited by this paper
• Clinical guidelines for establishing remission in patients with depression and anxiety.

  1999cited by this paper
• The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine.

  1998cited by this paper
• Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment.

  1998cited by this paper
• Three- to 5-year prospective follow-up of outcome in major depression

  1998cited by this paper
• The clinical course of unipolar major depressive disorders.

  1997cited by this paper
• When at first you don't succeed: sequential strategies for antidepressant nonresponders.

  1997cited by this paper
• The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression.

  1997cited by this paper
• The Inventory of Depressive Symptomatology (IDS): psychometric properties

  1996cited by this paper
• Definition and epidemiology of treatment-resistant depression.

  1996cited by this paper
• Residual symptoms after partial remission: an important outcome in depression

  1995cited by this paper
• Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale.

  1992cited by this paper
• CUMULATIVE ILLNESS RATING SCALE

  1968cited by this paper

• Eukaryotic initiation factor 4E: a key factor of traumatic stress-induced depression-related cognitive decline at different age

  2026influential citation
• From Monoamine Deficits to Multiscale Plasticity: Twenty-Five Years of Ketamine and the Neurophysiology of Depression.

  2026cites this paper
• Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis.

  2026cites this paper
• Metabolic profiling reveals potential biomarkers and underlying signaling pathways involved in mindfulness-based cognitive therapy-improved adolescent depression symptoms

  2026cites this paper
• [Efficacy and safety of super electroconvulsive therapy for treatment-resistant depression: a retrospective analysis of 292 cases].

  2026cites this paper
• Interactive dynamic modulation of antidepressant treatment response by serum interleukin-1β and Neuroticism at 12 weeks

  2026cites this paper
• The Efficacy of Combination Therapy With SWTX Capsule and Paroxetine for Depression: A Randomized Controlled Trial

  2026cites this paper
• Beyond first-line antidepressants: lithium, quetiapine, or esketamine? Integrating meta-analyses and preliminary head-to-head evidence

  2026cites this paper
• Associations of perioperative depression with sleep quality and physical activity levels in patients undergoing elective cardiac surgery: A prospective observational study

  2026cites this paper
• Neurobiological mechanisms of electroconvulsive therapy in major depressive disorder: structure-function coupling with gene expression and molecular mechanism

  2026cites this paper
• Gut microbiome signatures associated with depression and obesity

  2026cites this paper
• “Attacking” the Gut–Brain Axis with Psychobiotics: An Umbrella Review of Depressive and Anxiety Symptoms

  2026cites this paper
• Antidepressant exploration of moxidectin: Effects on behavior, neurotrophic factors and oxidative stress biomarkers in mice

  2026cites this paper
• Enhancing effect of cognitive control training on rTMS treatment in depression: A study protocol for a multicenter randomized controlled trial.

  2026cites this paper
• Reflections on Reductionist Clinical Psychological and Neuroscience Education: Putting the "Me" Back in Mental Disorders.

  2026cites this paper
• Stanford neuromodulation therapy for treatment‐resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy

  2026cites this paper
• Pharmacogenomics to optimise psychotropic prescribing: a survey of mental health professionals’ perceptions, knowledge, and educational needs

  2026cites this paper
• The effect of non-invasive transcranial focused ultrasound for depression on the default mode network: an open-label pilot trial

  2026cites this paper
• Effectiveness of intranasal esketamine in the treatment of patients with treatment-resistant depression: an observational study based on data collected in a Spravato treatment program at the Institute of Living, Hartford, CT.

  2026cites this paper
• Dose–Concentration Relationship and Clinical Outcomes of Duloxetine in Generalized Anxiety Disorder

  2026cites this paper
• Ketamine as a Mental Health Treatment.

  2026cites this paper
• Pharmacotherapy of major depressive disorder in older adults: from an evidence-informed stepwise algorithm to precision medicine.

  2026cites this paper
• Clinical benefits and considerations of dextromethorphan and bupropion administered separately for managing depression: A case report

  2026cites this paper
• Somatostatin-expressing neurons in the zona incerta regulate chronic stress response and modulate depression-like behaviors.

  2026cites this paper
• Major Depressive Disorder With Versus Without Psychosocial Triggers: A Secondary Analysis of a Prospective Cohort Study

  2026cites this paper
• Subgenual anterior cingulate cortex and antidepressant response to serotonergic and glutamatergic pharmacological treatments: a systematic review of neuroimaging studies.

  2026cites this paper
• Ketamine Combined With Psychotherapy as a Treatment for Resistant Depression in a Public European Hospital

  2026cites this paper
• Discovery of 2,4-Disubstituted Pyrimidine Derivatives as Novel Kir4.1 Inhibitors with Rapid-Onset Antidepressant Effect.

  2026cites this paper
• Single molecule long-read real-time amplicon-based sequencing of CYP2D6: a proof-of-concept with hybrid haplotypes

  2026cites this paper
• Accurate and Interpretable Prediction of Antidepressant Treatment Response from Receptor-informed Neuroimaging

  2026cites this paper
• Delay discounting correlates with depression but does not predict relapse after antidepressant discontinuation.

  2026cites this paper
• Leveraging topological indices and machine learning for advanced prediction of antidepressant drug properties

  2026cites this paper
• Efficacy of Personalized Connectivity-Guided Accelerated Brain Stimulation in a Naturalistic Treatment-Resistant Depression Population

  2026cites this paper
• Systematic review on relapse-prevention strategies following successful electroconvulsive therapy for major depressive disorder

  2026influential citation
• Biomarker innovations in precision psychiatry diagnostics and treatment strategies.

  2026cites this paper
• Improvement in avoidance in major depressive disorder: A 10‐month prospective study of depressive symptoms and personality traits

  2026cites this paper
• ATP-binding cassette transporter polymorphisms and the pharmacokinetics of oral esketamine.

  2026cites this paper
• Long-term effectiveness and side-effects of intranasal esketamine in treatment-resistant depression: real-world, single-arm study of over 100 sessions

  2026cites this paper
• Neuropsychological Perspectives on FDA-Approved At-Home Brain Stimulation for Depression: Integrating Music-Based Auditory Stimulation

  2026cites this paper
• Metabolic shifts, a consequence of hyperosmolarity, are a hallmark of mental disorders.

  2026cites this paper
• Oxidative Stress in Treatment-Resistant and Refractory Depression: A Hidden Therapeutic Target?

  2026cites this paper
• Gut Microbiota Dysbiosis in Depression: Pathological Correlations, Molecular Pathways, and Therapeutic Interventions

  2026cites this paper
• The development of positron emission tomography (PET) tracer for glutamate AMPA receptors and its application to human biology and clinics.

  2026cites this paper
• Efficacy of XRET in reducing anxiety symptoms and secondary effects on depression in adolescents with depressive disorder: a prospective non-randomized study.

  2026cites this paper
• Intestinal Flora Reconfiguration via Electroacupuncture: A Strategy to Counteract Depressive-Like Symptoms in Rats

  2026cites this paper
• Association Between Clinical Symptoms and Inflammatory Markers in First-Episode Unmedicated Patients with Major Depressive Disorder.

  2026cites this paper
• Positive bias in brain and behaviour as a mechanism of transcranial magnetic stimulation depression treatment.

  2026cites this paper
• Remotely Supervised Home-Based tDCS in Treatment-Resistant Depression: Feasibility, Effectiveness and EEG Biomarkers of Response

  2026cites this paper
• Non-implantable neuromodulation therapies compared to conventional treatments for major depression

  2026cites this paper
• Successful Use of Dextromethorphan-Bupropion for Severe, Treatment-Resistant Major Depressive Disorder.

  2026cites this paper
• Protocadherin 10, a member of cadherin superfamily, increases stress-susceptibility in chronic unpredictable stress-treated rats.

  2026cites this paper
• Predicting rTMS treatment efficacy in depression based on modular flexibility of functional connectivity.

  2026cites this paper
• Ingredients for Success: What Clients and Informal Caregivers Value in Depression Treatment A Concept Mapping Study.

  2026cites this paper
• Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy

  2026cites this paper
• 2-AG as a potential biomarker for predicting response to short-term fluoxetine treatment in a mouse model of depression

  2026cites this paper
• Synaptic effects of interleukin-6 on human iPSC-derived dopaminergic neurons.

  2026cites this paper
• Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression.

  2025cites this paper
• Exploring Male-Specific Synaptic Plasticity in Major Depressive Disorder: A Single-Nucleus Transcriptomic Analysis Using Bioinformatics Methods

  2025cites this paper
• Estimating the incidence of actionable drug-gene interactions in Japanese patients with major depressive disorder

  2025cites this paper
• Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des résultats du traitement antidépresseur à l’aide des scores de risque polygéniques : Rapport sur l’étude CAN-BIND-1

  2025cites this paper
• A group psychological intervention for postnatal depression in British mothers of South Asian origin - the ROSHNI-2 RCT.

  2025cites this paper
• From Stress to Synapse: The Neuronal Atrophy Pathway to Mood Dysregulation

  2025cites this paper
• Hemodynamic characteristics at baseline and following repeated transcranial magnetic stimulation treatment.

  2025cites this paper
• A systematic review of augmentation strategies for patients with major depressive disorder.

  2025cites this paper
• GPR120 internalization: a key mechanism for EPA in antidepressant action.

  2025cites this paper
• Innovative approaches in the treatment-resistant depression: exploring different therapeutic pathways

  2025cites this paper
• A Real-World Study on the Use, Effectiveness, and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression: INTEGRATE Study

  2025cites this paper
• Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data.

  2025cites this paper
• No relation between fMRI findings and thought distortion in mood disorder? A claim for new studies

  2025cites this paper
• Home-based transcranial direct current stimulation for major depressive disorder: 6-month follow-up from randomised sham-controlled trial and open-label treatment phases.

  2025cites this paper
• Serum multi-biomarkers for predicting relapse in patients with depressive disorders under psychopharmacotherapy.

  2025cites this paper
• Clinical Outcomes and Treatment Intensification across Depression Subtypes in Patients Receiving Stepwise Pharmacotherapy over 24 Months

  2025cites this paper
• Low Stability and Specificity of Polygenic Risk Scores for Major Psychiatric Disorders Limit their Clinical Utility.

  2025cites this paper
• Clinical Staging for Psychiatry and Psychology.

  2025cites this paper
• No changes in plasma brain-derived neurotrophic factor levels in treatment-resistant depression patients who underwent convulsive therapy

  2025cites this paper
• Person-centred care during treatment with nasal esketamine — a qualitative study

  2025cites this paper
• Peripheral and central inflammation in depression: How large is the gap and can we bridge it with PET neuroimaging and neural-derived extracellular vesicles?

  2025cites this paper
• Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK.

  2025cites this paper
• Assessing the utility of brain and gut cognitive electrophysiology for early prediction of treatment outcome in major depressive disorder

  2025cites this paper
• Comparative analysis of the risk of severe bacterial infection and septicemia in adolescents and young adults with treatment-resistant depression and treatment-responsive depression - a nationwide cohort study in Taiwan

  2025cites this paper
• Kynurenine pathway metabolites predict antianhedonic effects of electroconvulsive therapy in patients with treatment-resistant depression.

  2025cites this paper
• Association of optic neuritis with incident depressive disorder risk in a Korean nationwide cohort

  2025cites this paper
• A simple platelet biomarker is associated with symptom severity in major depressive disorder

  2025cites this paper
• A Stratified Precision Medicine Trial Targeting Selective Mechanisms of Alpha 2A Agonism as a Treatment for the Cognitive Biotype of Depression: The BIomarker Guided (BIG) Study for Depression

  2025cites this paper
• Neuroprotective role of geniposide-loaded UMSC nanovesicles in depression via P2ry12 downregulation.

  2025cites this paper
• Efficacy, Effectiveness, and Safety of Transcranial Magnetic Stimulation for Bipolar Depression: A Systematic Review and Meta-Analysis

  2025cites this paper
• Heart Rate Modulation and Clinical Improvement in Major Depression: A Randomized Clinical Trial with Accelerated Intermittent Theta Burst Stimulation

  2025cites this paper
• Titration of vagus nerve stimulation for difficult-to-treat depression and onset of response: Early insights from the RESTORE-LIFE study.

  2025cites this paper
• Integrating Psychopharmacology and Psychotherapy in the Treatment of Mood Disorders: A Comparative Analysis of Combined vs. Standalone Interventions

  2025cites this paper
• A machine learning approach to predict treatment efficacy and adverse effects in major depression using CYP2C19 and clinical-environmental predictors

  2025cites this paper
• Acute subanesthetic ketamine-induced effects on the mismatch negativity and their relationship to early and sustained treatment response in major depressive disorder

  2025cites this paper
• Effects of home-use transcranial direct current stimulation on clusters of depressive symptoms: an ancillary analysis of the PSYLECT study

  2025cites this paper
• Brain connectivity correlates of the impact of a digital intervention for individuals with subjective cognitive decline on depression and IL-18

  2025cites this paper
• Longitudinal associations between white matter integrity, early life adversities, and treatment response following cognitive-behavioral therapy in depression

  2025cites this paper
• Dissecting biological heterogeneity in major depressive disorder based on neuroimaging subtypes with multi-omics data

  2025cites this paper
• Agomelatine as adjunctive therapy with SSRIs or SNRIs for major depressive disorder: a multicentre, double-blind, randomized, placebo-controlled trial

  2025cites this paper
• Treatment target in schizophrenia: a critical review and a clinical suggestion.

  2025cites this paper
• Psychiatric Pharmacogenomic Testing: A Primer for Clinicians.

  2025cites this paper
• Assessment of complement cascade components in patients with major depressive disorder.

  2025cites this paper
• Serum levels of D-cycloserine predict antidepressant effects in pharmacologically enhanced intermittent theta-burst stimulation.

  2025cites this paper